ClinicalTrials.gg
Active, not recruitingNCT03505320ILUSTROUpdated Aug 31, 2026

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

A Phase 2 interventional study of zolbetuximab and oxaliplatin in Pharmacokinetics of Zolbetuximab, Gastric Cancer and Gastro-esophageal Junction (GEJ) Cancer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 804 studies in Stomach Neoplasms with a site in United States — 157 open to participants now, 239 under way, 12 of them phase 3. Stomach Neoplasms · United States.

Enrollment
171st of 686
143 · median 53
Started
2018
with 43 others
Phase 2
223 of 804
27 open now
Primary completion
2027-06
later than 99 of 238 live
Registered
415th of 804
by date

Among the 804 studies in Stomach Neoplasms with a site in United States, this one is the 171st largest by enrollment of the 686 interventional ones that give a count, is one of 44 that started in 2018, is one of 223 in phase 2, reaches primary completion later than 99 of the 238 other live ones, and was the 415th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

157 of the 804 studies in Stomach Neoplasms with a site in United States are open now. Recruiting first, the newest first:

152 more — sign in →

All 157 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 804 studies in Stomach Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer). Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to Claudin 18.2 in their tumor. This switches on the body's immune system to attack the tumor.

There is an unmet medical need to treat people with advanced cancer in and around the stomach or gastroesophageal junction cancer. This study will provide more information on zolbetuximab given by itself and in combination with other treatments in adults with advanced stomach or gastroesophageal junction cancer. The study is currently ongoing globally. People in this study will either be treated with zolbetuximab by itself, with zolbetuximab and chemotherapy, with zolbetuximab and a medicine called pembrolizumab, or zolbetuximab with chemotherapy and a medicine called nivolumab.

This study is ongoing, but enrollment in any of the treatment options has been completed. In addition, at this stage of the study, treatment in some of these treatment options has completed.

The main aim of this study is to check how well zolbetuximab controls tumors when given by itself.

Adults with cancer in and around the stomach or gastroesophageal junction cancer can take part. Their cancer is locally advanced unresectable or metastatic and has the CLDN18.2 marker in a tumor sample. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery.

Metastatic means the cancer has spread to other parts of the body. They may have been previously treated with standard therapies. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, have a specific heart condition or infections.

There are different treatments in the study. People who take part will receive just 1 of the treatments.

Treatment will be given in cycles. The treatment is given through a vein; this is called an infusion. Some people with advanced disease will have 1 infusion in 3 week (21-day) cycles. Some people will have several infusions in 6 week (42-day) cycles. Some people with cancer in and around the stomach or gastroesophageal junction who have surgery for their cancer will have a few infusions in 2-week (14-day) cycles. This will happen before and after they have surgery for their cancer.

People may receive chemotherapy for up to 6 months. Some people enrolled to received zolbetuximab and pembrolizumab, may have received pembrolizumab for up to 2 years.

People will visit the clinic on certain days during their treatment; there may be extra visits during the first cycle of treatment. The study doctors will check if people had any medical problems from zolbetuximab and the other study treatments. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken at certain visits with the option of giving a tumor sample after treatment has finished.

People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. After the clinic visits end some people will have a telephone health check every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not.

Read the detailed description

This is a study to assess the antitumor activity of zolbetuximab, an Immunoglobulin (IgG1) chimeric monoclonal antibody directed against CLDN18.2, in subjects with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and locoregional gastric or GEJ adenocarcinoma whose tumors are CLDN18.2 positive. For each cohort, the study consists of the following periods: pre-screening; screening; treatment; and follow-up for disease progression (or post-treatment follow-up for disease recurrence, which will be conducted for Cohort 5). In addition, there will be a survival follow-up period for Cohorts 1A, 4B, and 5 participants only. Tolerability of zolbetuximab in combination with pembrolizumab in Japanese participant(s) will be evaluated in Cohort 3A DLT assessment. Tolerability of zolbetuximab in combination with mFOLFOX6 and nivolumab in Japanese subject(s) will be evaluated in Cohort 4B, if Japanese subjects are not enrolled in the Cohort 4A DLT assessment.

03

Conditions studied

  • Pharmacokinetics of Zolbetuximab
  • Gastric Cancer
  • Gastro-esophageal Junction (GEJ) Cancer
  • Pharmacokinetics of Oxaliplatin
  • Pharmacokinetics of Fluorouracil Bolus (5-FU)

Keywords

  • zolbetuximab
  • oxaliplatin
  • fluorouracil
  • docetaxel
  • claudiximab
  • IMAB362
  • Gastro-Esophageal Junction cancer
  • locoregional gastric cancer
  • Pembrolizumab
  • Gastric cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subject eligible to participate if she is not pregnant and at least one of the following conditions applies:

    • Not a woman of (WOCBP) OR
    • WOCBP who agrees to follow the guidance throughout the treatment period and for at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study drugs.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • Female subject must agree not to donate ova starting at screening and throughout the study period, and for 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study drugs.
  • A sexually active male subject with a female partner(s) who is of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.
  • Male subject must agree not to donate sperm starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.
  • Subject has confirmed gastric or GEJ adenocarcinoma.
  • Cohorts 1-4: Subject has radiographically-confirmed, locally advanced, unresectable or disease within 28 days prior to the first dose of study treatment.
  • Subject's tumor is positive for CLDN18.2 expression demonstrating moderate to strong membranous staining as determined by central IHC testing.
  • Subject agrees to not participate in another interventional study while on treatment.
  • Subject has performance status 0 to 1.
  • Subject has predicted ≥ 12 weeks.
  • Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to the first dose of study treatment. In case of multiple central laboratory data within this period, the most recent data should be used.

    • (Hgb) ≥ 9 g/dL (transfusion is allowed, but post-transfusion Hgb [24 hours or later following transfusion] must be ≥ 9 g/dL)
    • (ANC) ≥ 1.5 × 109/L
    • ≥ 100 × 10\^9/L
    • Albumin ≥ 2.5 g/dL
    • Total ≤ 1.5 × (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN in subjects without liver metastases (≤ 5 × ULN if liver metastases are present)
    • Cohorts 1-4: Estimated ≥ 30 mL/min
    • Cohort 5: Serum creatinine ≤ 1.5 × ULN, or estimated creatinine clearance ≥ 50 mL/min for subjects with serum creatinine levels > 1.5 × ULN
    • /international normalized ratio and partial thromboplastin time ≤ 1.5 × ULN (except for subjects receiving anticoagulation therapy)

Specific to Cohort 1A:

  • Subject has according to 1.1 within 28 days prior to the first dose of study treatment per investigator assessment. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before enrollment, the lesion must either be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
  • Subject has disease progression on or after at least 2 prior regimens for their advanced disease, including fluoropyrimidine and platinum-containing chemotherapy, and if appropriate, /neu-targeted therapy and all associated side effects have resolved to grade 1 or less.
  • Subject must have an additional available tumor specimen collected within 3 months prior to the first dose of study treatment.
  • Subject must be an appropriate candidate for a tumor and is amenable to undergo a tumor biopsy during the screening period (if applicable) and treatment period as indicated in the Schedule of Assessments.

Specific to Cohort 2:

  • Subject has measurable disease according to RECIST 1.1 within 28 days prior to the first dose of study treatment per investigator assessment. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before enrollment, the lesion must either be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
  • Subject has not received prior systemic anti-cancer therapy for their advanced disease (subject may have received and/or fluorouracil-containing adjuvant chemotherapy as long as it has been completed ≥ 6 months before the first dose of study treatment).
  • Subject has a gastric or GEJ tumor that is HER2-negative as determined by local or central testing.
  • Subject must have an additional available tumor specimen collected within 3 months prior to the first dose of study treatment.
  • Subject must be an appropriate candidate for a tumor biopsy and is amenable to undergo a tumor biopsy during the screening period (if applicable) and treatment period as indicated in the Schedule of Assessments.

Specific to Cohort 3A:

  • Subject has radiologically evaluable disease (measurable and/or non-measurable) according to RECIST 1.1, per local assessment, ≤ 28 days prior to the first dose of study treatment. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before enrollment, the lesion must either be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
  • Subject has disease progression on or after at least 2 prior regimens for their advanced disease, including fluoropyrimidine and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy.
  • Subject has not received prior therapy.

Specific to Cohort 4A and 4B:

  • Subject has radiologically evaluable disease.
  • Subject has not received prior systemic anti-cancer therapy for their advanced disease.
  • Subject has a gastric or GEJ tumor that is HER2-negative as determined by local or central testing.
  • Subject has not received prior checkpoint inhibitor therapy.

Specific to Cohort 4B Only:

  • Subject must have an additional available tumor specimen collected within 3 months prior to the first dose of study treatment.
  • Subject must be an appropriate candidate for a tumor biopsy and is amenable to undergo a tumor biopsy during the screening period (if applicable) and treatment period.

Specific to Cohort 5 Only:

  • Subject has new histologically confirmed primary gastric or GEJ adenocarcinoma that is amenable to curative resection.
  • Subject has locoregional, resectable gastric or GEJ adenocarcinoma. GEJ may include type I-III Siewert classification. Clinical stage will be determined by endoscopic ultrasound (EUS) and/or CT or MRI. Diagnostic laparoscopy may be used as per institutional guidelines and clinical practices.
  • Subject meets one of the following criteria of locoregional disease by clinical TNM staging:
  • GEJ: cT2,N0 (high risk-lesions: ≥ 3 cm, poorly differentiated), cT1b-cT2,N+ or cT3-cT4a,Any N.
  • Gastric: T2 to T4a, and/or N1-3,M0.
  • Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing

Exclusion criteria

Exclusion Criteria:

  • Subject has had prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.
  • Subject has known immediate or delayed or to any component of study treatment.
  • Subject has received other agents or devices concurrently or within 28 days prior to first dose of study treatment.
  • Subject has received systemic therapy, including systemic 14 days prior to first dose of study treatment.
  • Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent recurrent vomiting.
  • Subject has significant gastric bleeding and/or untreated gastric ulcers that would preclude the subject from participation.
  • Subject has history of central nervous system and/or carcinomatous meningitis from gastric/GEJ cancer.
  • Subject has a known history of a positive test for (HIV) infection or known active (positive hepatitis B surface antigen [HBsAg]) or infection.
  • Subject has had within 6 months prior to first dose of study treatment any of the following: unstable angina, myocardial infarction, ventricular arrhythmia requiring intervention or hospitalization for heart failure.
  • Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to the start of study treatment.
  • Subject has active disease that has required systemic treatment within the past 3 months prior to the start of study treatment.
  • Subject has a disease or co-morbidity that may adversely affect the safe delivery of treatment within this study or make the subject unsuitable for study participation.
  • Subject has psychiatric illness or social situations that would preclude study compliance.
  • Subject has had a major surgical procedure ≤ 28 days before start of study treatment.
  • Subject is without complete recovery from a major surgical procedure ≤ 14 days before start of study treatment

    • Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days (Cohorts 1 and 3A) and ≤ 28 days (Cohorts 2 and 4A or 4B) prior to start of study treatment and has NOT recovered from any related toxicity.
    • Subject has another , for which treatment is required.
  • Cohort 2, 4 and 5 Only, subject has any of the following:

    • Prior severe allergic reaction or intolerance to any component of mFOLFOX6 or FLOT chemotherapeutics in this study
    • Known dihydropyrimidine dehydrogenase deficiency (DPD).
    • Known peripheral neuropathy > Grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the subject ineligible).
    • Sinusoidal obstruction syndrome, formerly known as veno-occlusive disease, if present, should be stable or improving.
    • History of clinically significant ventricular arrhythmias.
    • > 450 msec for male subjects; QTc interval > 470 msec for female subjects.
    • History or family history of congenital long QT syndrome.
    • Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate controlled atrial fibrillation for > 1 month prior to first dose of study treatment are eligible).
  • Cohorts 3A, 4A and 4B Only, subject has any of the following:

    • Ongoing or previous autoimmune disease or interstitial lung disease, active diverticulitis or gastrointestinal ulcerative disease, or solid organ or stem cell transplant (for Cohort 4) or other uncontrolled or clinically significant medical disorders.
    • Type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy or skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment are allowed.
    • Known history of serious hypersensitivity reaction to a known ingredient of pembrolizumab or nivolumab.
  • Cohort 4B Only: Subjects has microsatellite instability-high or mismatch repair deficient tumors.
  • Cohort 5 Only, subject has either of the following:

    • Subject cannot undergo curative resection per the investigator's judgment
    • Subject meets the following criterion of locoregional disease by clinical TNM staging: cT1N0.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    zolbetuximab (Cohort 1A)

    Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met.

    Drug: zolbetuximab

  • Experimental
    mFOLFOX6 plus zolbetuximab (Cohort 2)

    Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive up to 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous \[IV\] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.

    Drug: zolbetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: fluorouracil · Drug: folinic acid

  • Experimental
    Pembrolizumab plus zolbetuximab (Cohort 3A)

    Participants will be treated with zolbetuximab and pembrolizumab on a 21-day cycle. Loading dose of zolbetuximab will be administered at cycle 1, day 1 followed by maintenance dose of zolbetuximab once every 3 weeks (Q3W). Pembrolizumab will be administered to 3 to 6 subjects at a intravenously on day 1 of every 21-day cycle and will be infused 1 hour after the zolbetuximab infusion is completed. Tolerability and safety of zolbetuximab in combination with pembrolizumab will be evaluated during the 3-week dose-limiting toxicity (DLT) assessment period. If this cycle 1 dose is not tolerable, a lower dose of zolbetuximab in combination with pembrolizumab will subsequently be evaluated.

    Drug: zolbetuximab · Drug: Pembrolizumab

  • Experimental
    Zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4A/4B)

    Participants will be treated with zolbetuximab and mFOLFOX6, nivolumab on a 42-day cycle. Cohort 4A: Loading dose of zolbetuximab in combination with nivolumab and mFOLFOX6 on cycle 1 day 1, followed by zolbetuximab in combination with nivolumab and mFOLFOX6 q2w \[days 15 and 29\] (1 cycle = 6 weeks). Tolerability and safety of zolbetuximab in combination with nivolumab, mFOLFOX6 will be evaluated during the 3-week DLT assessment period. If cycle 1 dose is not tolerable, a lower dose of dose zolbetuximab in combination with nivolumab and mFOLFOX6 will be subsequently evaluated. Cohort 4B: Subjects will be treated with the combination of zolbetuximab, mFOLFOX6 and nivolumab at the dose deemed tolerable in Cohort 4A. Subjects will receive up to 12 mFOLFOX6 treatments (4 cycles). For Cohorts 4A and 4B, beginning at cycle 5, subjects may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab and nivolumab for the remainder of the study per investigator's discretion.

    Drug: zolbetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: fluorouracil · Drug: folinic acid · Drug: nivolumab

  • Experimental
    Zolbetuximab in combination with FLOT (Cohort 5)

    Participants will be treated with zolbetuximab \& FLOT for a total of eight 2-week cycles. 4 cycles preoperatively \& 4 cycles postoperatively 6-12 weeks after surgery. Preoperative: Participants will receive zolbetuximab loading dose on cycle 1 day 1, followed by FLOT on cycle 1 day 2. For cycles 2-4, participants may receive zolbetuximab maintenance dose in combination with FLOT, dosed on day 1 of each cycle. However, dosing may be split over 2 days with zolbetuximab administration on day 1 \& FLOT on day 2. Post operative: Participants will receive zolbetuximab loading dose on cycle 5 day 1, followed by FLOT on cycle 5 day 2. For cycles 6-8, participants may receive zolbetuximab maintenance dose in combination with FLOT, dosed on day 1 of each cycle. However, dosing may be split over 2 days with zolbetuximab administration on day 1 and FLOT on day 2. For participants who experience a DLT during preoperative treatment on the loading dose, the postoperative loading dose may be lowered.

    Drug: zolbetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: fluorouracil · Drug: folinic acid · Drug: Docetaxel

Interventions

  • Zolbetuximab will be administered as a minimum 2-hour IV infusion.

    Also known as: IMAB362

  • Oxaliplatin will be administered as a 2-hour IV infusion.

  • Leucovorin will be administered as a 2-hour IV infusion.

  • Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.

  • Pembrolizumab will be administered intravenously over 30 minutes.

  • Folnic acid will be administered as a 2-hour IV infusion.

  • Nivolumab will be administered intravenously according to institutional standards.

  • Docetaxel will be administered as a 1-hour IV infusion.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1)

    The ORR is defined as the proportion of participants with complete or partial objective response based on Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 (assessed by an independent review committee (IRC)).

    Time frame: Up to 3 months

Secondary outcomes

  1. Pharmacokinetics (PK) of zolbetuximab: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf) (Cohorts 1A, 2, 3A, 4 and 5)

    AUCinf will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  2. PK of zolbetuximab: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity Percentage (AUCinf (%extrap)) (Cohorts 1A, 2, 3A, 4 and 5)

    AUCinf (%extrap) will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  3. PK of zolbetuximab: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast) (Cohorts 1A, 2, 3A, 4 and 5)

    AUClast will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  4. PK of zolbetuximab: Area Under the Concentration-Time Curve from the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) (Cohorts 1A, 2, 3A, 4 and 5)

    AUCtau will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  5. PK of zolbetuximab: Maximum Concentration (Cmax) (Cohorts 1A, 2, 3A, 4 and 5)

    Cmax will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  6. PK of zolbetuximab: Concentration Immediately Prior to Dosing (Ctrough) (Cohorts 1A, 2, 3A, 4 and 5)

    Ctrough will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  7. PK of zolbetuximab: Time of Maximum Concentration (Tmax) (Cohorts 1A, 2, 3A, 4 and 5)

    Tmax will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  8. PK of zolbetuximab: Terminal Elimination Half-life (T1/2) (Cohorts 1A, 2, 3A, 4 and 5)

    T1/2 will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  9. PK of zolbetuximab: Time of the last measurable concentration (Tlast) (Cohorts 1A, 2, 3A, 4 and 5)

    Tlast will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  10. PK of zolbetuximab: Clearance (CL) (Cohorts 1A, 2, 3A, 4 and 5)

    CL will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  11. PK of zolbetuximab: Volume of Distribution During the Terminal Phase (Vz) (Cohorts 1A, 2, 3A, 4 and 5)

    Vz will be derived from the PK serum samples collected.

    Time frame: Up to 16 months

  12. PK of oxaliplatin: AUCinf (Cohort 2)

    AUCinf will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  13. PK of oxaliplatin: AUCinf (%extrap) (Cohort 2)

    AUCinf (%extrap) will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  14. PK of oxaliplatin: AUClast (Cohort 2)

    AUClast will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  15. PK of oxaliplatin: Cmax (Cohort 2)

    Cmax will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  16. PK of oxaliplatin: Tmax (Cohort 2)

    Tmax will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  17. PK of oxaliplatin: T1/2 (Cohort 2)

    T1/2 will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  18. PK of oxaliplatin: Tlast (Cohort 2)

    Tlast will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  19. PK of oxaliplatin: CL (Cohort 2)

    TL will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  20. PK of oxaliplatin: Vz (Cohort 2)

    Vz will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  21. PK of fluorouracil bolus (5-FU): AUCinf (Cohort 2)

    AUCinf will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  22. PK of fluorouracil bolus (5-FU): AUCinf (%extrap) (Cohort 2)

    AUCinf (%extrap) will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  23. PK of fluorouracil bolus (5-FU): AUClast (Cohort 2)

    AUClast will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  24. PK of fluorouracil bolus (5-FU): Cmax (Cohort 2)

    Cmax will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  25. PK of fluorouracil bolus (5-FU): Tmax (Cohort 2)

    Tmax will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  26. PK of fluorouracil bolus (5-FU): T1/2 (Cohort 2)

    T1/2 will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  27. PK of fluorouracil bolus (5-FU): Tlast (Cohort 2)

    Tlast will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  28. PK of fluorouracil bolus (5-FU): CL (Cohort 2)

    CL will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  29. PK of fluorouracil bolus (5-FU): Vz (Cohort 2)

    Vz will be derived from the PK plasma samples collected.

    Time frame: Up to 16 months

  30. Safety and tolerability assessed by adverse events (AEs) (Cohorts 1A, 2, 3A, 4 and 5)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 16 months

  31. Number of participants with electrocardiogram (ECG) abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 14 months

  32. Number of participants with vital signs abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 14 months

  33. Number of participants with European Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)

    Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

    Time frame: Up to 14 months

  34. Number of participants with laboratory assessments abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 14 months

  35. Number of anti-drug antibody (ADA) Positive Participants (Cohorts 1A, 2, 3A, 4 and 5)

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Up to 16 months

  36. Health Related Quality of Life (HRQoL) measured by the Quality of Life Questionnaire - Core Questionnaire (QLQ-C30) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)

    The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.

    Time frame: Up to 16 months

  37. HRQoL measured by the Oesophago-Gastric Module (EORTC QLQ-OG-25) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)

    The EORTC-QLQ-OG25 instrument evaluates GC- and GEJC-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion.

    Time frame: Up to 16 months

  38. HRQoL measured by the Global Pain (GP) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)

    The GP instrument is a single assessment of overall pain.

    Time frame: Up to 16 months

  39. HRQoL measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)

    The EQ-5D-5L is a standardized instrument developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. The EQ-5D-5L is a 5-item self-reported measure of functioning and wellbeing, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

    Time frame: Up to 16 months

  40. HRQoL measured by the Health Resource Utilization (HRU) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)

    Health resource utilization questionnaire to assess the number of office visits, hospital stays and other healthcare resource utilization that occur outside of the clinical trial.

    Time frame: Up to 16 months

  41. Disease Control Rate (DCR) of zolbetuximab as a single agent by investigator assessment (Cohort 1A)

    The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.

    Time frame: Up to 3 months

  42. DCR of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)

    The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.

    Time frame: Up to 13 months

  43. DCR of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)

    DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.

    Time frame: up to 13 months

  44. DCR of zolbetuximab as a single agent by independent central reader (Cohort 1A)

    The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.

    Time frame: Up to 3 months

  45. DCR of zolbetuximab in combination with mFOLFOX6 by Independent central reader (Cohort 2)

    The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.

    Time frame: Up to 13 months

  46. Duration of Response (DOR) of zolbetuximab as a single agent by investigator assessment (Cohort 1A)

    DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.

    Time frame: Up to 3 months

  47. DOR of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)

    DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.

    Time frame: Up to 13 months

  48. DOR of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)

    DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.

    Time frame: up to 13 months

  49. DOR of zolbetuximab as a single agent by independent central reader (Cohort 1A)

    DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.

    Time frame: Up to 3 months

  50. DOR of zolbetuximab in combination with mFOLFOX6 by independent central reader (Cohort 2)

    DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.

    Time frame: Up to 13 months

  51. Progression Free Survival (PFS) of zolbetuximab as a single agent by investigator assessment (Cohort 1A)

    PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.

    Time frame: Up to 3 months

  52. PFS of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)

    PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.

    Time frame: Up to 13 months

  53. PFS of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)

    PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.

    Time frame: up to 13 months

  54. PFS of zolbetuximab as a single agent by independent central review (Cohort 1A)

    PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.

    Time frame: Up to 3 months

  55. PFS of zolbetuximab in combination with mFOLFOX6 by independent central review (Cohort 2)

    PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.

    Time frame: Up to 13 months

  56. ORR of zolbetuximab as a single agent by investigator assessment (Cohort 1A)

    The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.

    Time frame: Up to 3 months

  57. ORR of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)

    The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.

    Time frame: Up to 13 months

  58. ORR of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)

    The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.

    Time frame: up to 13 months

  59. ORR of zolbetuximab in combination with mFOLFOX6 by independent central reader (Cohort 2)

    The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.

    Time frame: Up to 13 months

  60. ORR of zolbetuximab in combination with pembrolizumab by independent central reader (Cohort 3A)

    The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.

    Time frame: Up to 5 months

  61. Overall Survival (OS) of zolbetuximab as a single agent (Cohort 1A)

    OS is defined as the time from the date of treatment start until the documented date of death from any cause.

    Time frame: Up to 7 months

  62. OS of zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4B)

    OS is defined as the time from the date of treatment start until the documented date of death from any cause.

    Time frame: up to 56 Months

  63. OS of zolbetuximab in combination with FLOT (Cohort 5)

    OS is defined as the time from the date of treatment start until the documented date of death from any cause.

    Time frame: Up to 72 months

  64. Percentage of participants with surgical complications (Cohort 5)

    Percentage of participants with surgical complications will be reported.

    Time frame: Up to 8 months

  65. Percentage of participants with surgical mortality as defined by death within 30 days of surgery (Cohort 5)

    Percentage of participants with surgical mortality as defined by death within 30 days of surgery will be reported.

    Time frame: Up to 30 days

  66. Percentage of participants able to complete preoperative chemotherapy (Cohort 5)

    Percentage of participants able to complete preoperative chemotherapy will be reported.

    Time frame: Up to 2 months

  67. Percentage of participants with perioperative mortality and morbidity at 30 days and 90 days post last dose (Cohort 5)

    Percentage of participants with perioperative mortality and morbidity at 30 days and 90 days post last dose will be reported.

    Time frame: Up to 3 months

  68. Percentage of participants able to start postoperative chemotherapy (Cohort 5)

    Percentage of participants able to start postoperative chemotherapy will be reported.

    Time frame: Up to 7 months

  69. Percentage of participants able to complete postoperative chemotherapy (Cohort 5)

    Percentage of participants able to complete postoperative chemotherapy will be reported.

    Time frame: Up to 9 months

  70. Percentage of participants with radiological response at restaging (Cohort 5)

    Radiological response will include complete response and partial response.

    Time frame: Up to 5 months

  71. Percentage of subjects with pathological response (ypTNM) (Cohort 5)

    Pathological response (ypTNM) will include ypCR, ypPR

    Time frame: Up to 5 months

  72. Disease-free Survival (DFS) (Cohort 5)

    DFS is defined as the time from date of treatment start until the date of radiological disease recurrence or until death due to any cause, whichever is earliest.

    Time frame: Up to 70 months

  73. Minimal Residual Disease (Cohort 5)

    Minimal residual disease and disease recurrence as measured by circulating tumor DNA (ctDNA) will be summarized.

    Time frame: Up to 37 months

07

Study locations

21 sites
08

References and documents

Publications

  • Shitara K, Shoji H, Fazio N, Lonardi S, Lee KW, Bai LY, Yamaguchi K, Metges JP, Masi G, Smith D, Kim TY, Matsangou M, Shrivastava A, Zhou M, Hill J, Guerrero A, Wang X, Zaanan A, Klempner SJ. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026 Jun;32(6):2182-2190. doi: 10.1038/s41591-026-04306-9. Epub 2026 Mar 16. PubMed 41840238 ↗
  • Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Jun 2027, 108 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 108 months is above that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 23, 2018
StartActual
Jun 29, 2018
Primary completionEst.
Jun 30, 2027
CompletionEst.
May 31, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03505320
Responsible party
Sponsor
First posted
Apr 23, 2018
Start date
Jun 29, 2018
Primary completion
Jun 30, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Global Medical Lead
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion